ASCO 2023 | Bendamustine-bortezomib-dexamethasone in R/R multiple myeloma
Despite advances in the management of multiple myeloma and the inclusion of immunotherapy in all lines of treatment, some patients remain refractory to immuno-oncology approaches. In this interview, Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, shares results from a retrospective, real-world analysis, in which the combination of bendamustine, bortezomib, and dexamethasone (BVD) was evaluated as salvage therapy for relapsed/refractory (R/R) multiple myeloma. The findings suggest that BVD may be an effective therapeutic option for patients with R/R multiple myeloma, even in challenging cases. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini; Pfizer; Sanofi/Aventis; SERVIER; Stemline Therapeutics; Takeda Consulting or Advisory Role – Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini; Pfizer; Sanofi; SERVIER; Stemline Therapeutics; Takeda Speakers’ Bureau – Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini; Pfizer; Sanofi/Aventis; SERVIER; Stemline Therapeutics; Takeda
